Thiazovivin: ROCK Inhibitor for Enhanced Cell Reprogramming and Stem Cell Survival

Executive Summary: Thiazovivin (N-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide, MW 311.36, CAS No. 1226056-71-8) is a potent inhibitor of the ROCK signaling pathway, facilitating the reprogramming of fibroblasts into induced pluripotent stem cells (iPSCs) and improving human embryonic stem cell (hESC) survival, especially post-trypsinization (APExBIO product page). The compound is effective at concentrations that provide at least 15.55 mg/mL solubility in DMSO and is supplied with ≥98% purity. Thiazovivin's mechanism is distinct yet synergistic with SB 431542 and PD 0325901, making it valuable for differentiation therapy research (Xie et al., 2021). The product is widely used in protocols requiring enhanced cell reprogramming efficiency and survival (related article).

Biological Rationale

Cellular plasticity, defined as the ability of somatic cells to change fate or phenotype, underpins regenerative medicine and cancer research (Xie et al., 2021). ROCK (Rho-associated coiled-coil containing protein kinase) signaling is central to cytoskeletal organization, cell adhesion, and apoptosis. Inhibition of ROCK has been shown to reduce dissociation-induced apoptosis in hESCs and to enhance reprogramming efficiency in fibroblasts (APExBIO). Thiazovivin, as a selective and potent ROCK inhibitor, addresses these mechanisms by modulating actin-myosin contractility and cell survival pathways. The rationale for its use extends to improving experimental reproducibility and viability in stem cell workflows (see contrast with thought-leadership article).

Mechanism of Action of Thiazovivin

Thiazovivin directly inhibits the ROCK1 and ROCK2 isoforms at nanomolar concentrations, preventing phosphorylation of downstream targets such as myosin light chain (MLC). This inhibition results in decreased actin stress fiber formation and reduced apoptosis, particularly during cell dissociation or reprogramming protocols. When combined with inhibitors of TGF-β (e.g., SB 431542) and MEK (e.g., PD 0325901), Thiazovivin synergistically enhances iPSC induction by minimizing cytoskeletal stress and promoting survival of single cells. Its solid-state stability and high solubility in DMSO (≥15.55 mg/mL) enable reproducible dosing and integration into complex media. The compound’s chemical structure (N-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide) confers specificity for the ATP-binding site of ROCK kinases (Xie et al., 2021).

Evidence & Benchmarks

• Thiazovivin increases iPSC colony formation efficiency by up to 4-fold when used at 2–5 μM with SB 431542 and PD 0325901 during fibroblast reprogramming (Xie et al., 2021).
• hESC survival post-trypsinization improves from <10% to >70% with 2 μM Thiazovivin in standard media (APExBIO).
• The compound demonstrates ≥98% purity by HPLC and mass spectrometry analyses (manufacturer's certificate; APExBIO product page).
• Thiazovivin displays robust solubility (≥15.55 mg/mL in DMSO at 25°C) and retains stability for up to six months at -20°C as a solid (APExBIO).
• When integrated into protocols for cancer modeling and disease research, Thiazovivin supports epigenetic modulation strategies targeting cell plasticity (internal: mechanistic perspective).

Applications, Limits & Misconceptions

Thiazovivin is optimized for stem cell research, regenerative medicine, and disease modeling workflows requiring high-efficiency reprogramming and robust cell survival. Its primary applications include:

• Enhancing reprogramming of human/mouse fibroblasts to iPSCs.
• Improving survival and expansion of hESCs post-dissociation.
• Supporting studies on cytoskeletal dynamics and cell fate manipulation.

For a strategic integration discussion, see this article, which is broadened here by direct citation of quantitative benchmarks and protocol limits.

Common Pitfalls or Misconceptions

• Thiazovivin does not induce pluripotency on its own; it requires co-factors such as SB 431542 and PD 0325901 for reprogramming enhancement.
• Long-term storage of DMSO solutions is not recommended; stability is best preserved as a solid at -20°C (APExBIO).
• The compound is not effective in protocols unrelated to ROCK signaling or cell adhesion/survival.
• Use in animal or clinical studies requires additional safety validation beyond research-grade purity.
• Not all cell types respond identically; efficacy may vary with cell lineage and culture conditions.

Workflow Integration & Parameters

Thiazovivin (A5506, APExBIO) is typically supplied as a dry solid, stored at -20°C, and shipped with blue ice to maintain stability. For working solutions, dissolve in DMSO to at least 15.55 mg/mL. For cell culture, dilute to 2–5 μM in final medium immediately prior to use. Do not store DMSO solutions for more than 24 hours at room temperature or one week at -20°C. The product is compatible with standard stem cell media and most reprogramming protocols. For additional workflow-specific guidance and to see how Thiazovivin sets new efficiency benchmarks, refer to this protocol-focused article—the present dossier updates it with current stability and purity data.

Conclusion & Outlook

Thiazovivin stands as a validated, highly pure ROCK inhibitor that enables efficient, reproducible cell reprogramming and survival in stem cell research. Its robust chemical profile and well-characterized mechanism of action position it as a cornerstone in the evolving landscape of regenerative medicine and differentiation therapy. By integrating precise dosing, quality control, and mechanistic synergy with established small molecules, Thiazovivin facilitates next-generation protocols for disease modeling and therapeutic development. For authoritative information and ordering, consult the APExBIO Thiazovivin product page.